UK NICE Releases MedTech Innovation Briefing for AlignRT
18 May 2018. The UK National Institute for Health and Care Excellence (NICE) this week released a MedTech Innovation Briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery, Vision RT’s market leading solution for Surface Guided Radiation Therapy (SGRT).
This briefing summarised the evidence for the use of AlignRT in this indication, stating that studies “suggest that AlignRT is as effective as existing position monitoring systems for people having SRS to treat brain tumours” and that AlignRT “does not use potentially uncomfortable patient frames or bite plates, additional ionising radiation, or separate radiation sources or tracking systems.”
In addition, the MIB mentioned potentially favourable costs for the system in comparison to comparable therapies for the same patient group.
MIBs are NICE advice. They are designed to support NHS and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies.
Thomas Carter, Senior Director of Global Marketing at Vision RT, stated “NICE use rigorous processes to assess new technology and are a key part of the adoption of clinical and health economic best practice, not only in the UK but also elsewhere in the world. We are very encouraged by this Medtech Innovation Briefing which covers an application for which hundreds of Vision RT SGRT systems have been deployed to leading cancer centres worldwide.”
“AlignRT is already used in the UK for intracranial stereotactic radiosurgery, as well as breast cancer and other conditions, where patients may benefit not only from the accuracy of the product but also avoiding the need for radiotherapy tattoos.”